• Twitter
  • Facebook

Terms & conditions  Cookie policy   Privacy policy

Copyright © Cancer52. All rights reserved.

Cancer52 is registered as a charity in England and Wales (1174569) and a company limited by guarantee in England and Wales (7994413)

17 Jul 2019

Cancer52 and PHE/NCRAS are delighted to be able to share a film and a report of the very successful Developments in Data for Rare and Less Common Cancers event held on 22nd May 2019.

The report provides a written overview of the whole event and the film includes snippet...

10 Jul 2019

On Wednesday 10th July we launched a new report, ‘Getting a better deal for people with rare and less common cancers: what we can learn from patients’ at an event for MPs at Portcullis House, Houses of Parliament. 

The report was based on a patient survey conducted in 2...

29 Nov 2018

Cancer52, together with use MY data, have jointly produced a briefing document on what The National Data Opt-out means for cancer patients.

Visit the joint Cancer52 and use MY data ‘Patient and Carer Voice’ stand at the Britain Against Cancer 2018 conference on Tuesday...

20 Nov 2018

We are delighted that Cancer52 features in this month's New Statesman's Oncology Supplement, published to coincide with this year's Britain Against Cancer conference.

The supplement features articles from Cally Palmer, National Cancer Director at NHS England, Lynda Thom...

31 Oct 2018

We are pleased to announce that Cancer52 is recruiting trustees to its board to support the future development and growth of the organisation’s work, in line with an ambitious new strategic plan that was approved earlier this year. 

The role description, per...

30 Oct 2018

In June, at the PHE Cancer Services, Data and Outcomes Conference 2018, Cancer52 worked with the National Cancer Registration and Analysis Service (NCRAS), part of PHE, to highlight the importance of access to data for rare and less common cancers. 

As well as running a...

17 Oct 2018

We're excited to announce the publication of our new briefing document 'Getting a better deal for people with rare and less common cancers: the next ten years' which we are publishing on Wednesday 17 October at our annual all stakeholder briefing.

During our consul...

28 Sep 2018

Yesterday afternoon, the Bristol-Myers Squibb (BMS) UK team cycled into Uxbridge, marking the end of this year’s Country 2 Country 4 Cancer (C2C4C) cycling challenge! Picking up from the French BMS team in Tours, France, the UK team covered over 720km of French vineyar...

18 Sep 2018

We are now over one week into this years’ Bristol-Myers Squibb (BMS) Country 2 Country 4 Cancer (C2C4C) cycling challenge, meaning we are almost at the halfway stage. The riders have clocked up around 1,500 kilometres so far, raising money for various European cancer c...

13 Sep 2018

This Monday, the Bristol-Myers Squibb (BMS) Country 2 Country 4 Cancer (C2C4C) bike ride set off for another year. It's a pan-European bike ride involving six country teams across Europe, and the last stretch from Tours in France back to the BMS London offices will com...

Please reload